Wielkość rynku medycznego bazującego na konopiach szacowana jest w 2028 roku w Polsce na 2 mld EUR oraz na 58 mld EUR w całej Europie.

Telehorse SA (“Issuer”) informs that on 08/06/2019 the Management signed copy of the letter of intent signed by Grupa Blue Medica sp. z o.o. with its registered office in Zgierz (“Partner”).

Grupa Blue Medica is the owner of a Polish nationwide network of thirteen modern medical facilities.

The cooperation of Cannabis Poland and the Partner provides for medical consultations regarding the creation of a network of specialized stores with products of cannabis origin and cooperation in the construction of a network of medical clinics specializing in treating patients with cannabinoid-containing cannabis-containing products, including THC below 0.2% and above 0.2%, as well as know-how related to the construction of medical clinics.

The contract has been concluded for a period of three months. During this time, the parties will make efforts to sign the “Cooperation Agreement”.

The Issuer indicates that after changing the name to ‘Cannabis Poland’, it will be conducting business in the production and sale of pharmaceutical and medical products with a focus on vaporizing products containing cannabinoids made from hemp. Vaporizing rich in cannabinoids is considered the most effective, effective and economical method of taking cannabinoids.

Cannabinoids are used in anti-inflammatory, analgesic, anxiolytic, antipsychotic and antispasmodic cures. They are used in Alzheimer’s and Parkinson’s diseases, sclerosis, leukemia, diabetes, asthma, epilepsy, spinal cord injuries, migraines, and withdrawal therapies. They help with rheumatic pains, and have antiemetic and appetite stimulating properties, which is essential for people during chemotherapy. They can also be used in the process of rehab while fighting the addiction of smoking and heroin. Cannabinoids are also used to treat drug-resistant epilepsy.

The size of the medical market, based on cannabis, is estimated in 2028 in Poland at EUR 2 billion and at EUR 58 billion throughout Europe.